Avascular Necrosis Treatment in India
Get Avascular Necrosis Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Avascular Necrosis Treatment in UAE
Avascular Necrosis Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Avascular Necrosis (AVN), also known as osteonecrosis, is a debilitating condition caused by disrupted blood supply to bone tissue, most commonly affecting the femoral head, leading to bone collapse and severe joint destruction if untreated. Modern interventions — ranging from core decompression with stem cell augmentation and free vascularized fibular grafting to total hip or knee arthroplasty using robotic-assisted systems — achieve excellent outcomes, with joint-preservation success rates of 70–85% in early-stage disease and prosthetic survivorship exceeding 95% at 10 years in advanced cases. GAF Healthcare connects international patients with India's and the UAE's top-tier orthopedic centers, offering JCI/NABH-accredited expertise, cutting-edge imaging and surgical technology, and end-to-end medical travel coordination at a fraction of Western costs.
Hospital Stay: 3–7 days (joint-preservation procedures) to 5–10 days (total joint arthroplasty) • Total Stay in Country (Fit-to-Fly): 3–6 weeks (joint-preservation/core decompression); 6–8 weeks (total hip or knee replacement) • Success Rate: 70–85% (joint-preservation, Stages I–III); >95% prosthetic survivorship at 10 years (total arthroplasty)
What Is It?
Avascular Necrosis (AVN) occurs when the osseous microvascular supply is interrupted, triggering ischemic necrosis of trabecular bone and marrow. The femoral head is the most frequently involved site, accounting for approximately 20,000–30,000 new cases annually in the United States alone, but AVN also affects the humeral head, femoral condyles, talus, scaphoid, and lunate. As necrotic bone loses its structural integrity, subchondral fracture and subsequent articular collapse progress through well-defined radiographic stages described by the Association Research Circulation Osseous (ARCO) classification and the Ficat-Arlet system, ultimately culminating in secondary osteoarthritis if the disease is not intercepted early.
The physiological cascade begins with a vascular insult — precipitated by corticosteroid therapy, excessive alcohol use, sickle cell disease, dysbaric exposure, trauma, coagulopathies, or idiopathic causes — that reduces intraosseous blood flow below the critical threshold necessary for osteocyte survival (approximately 2–5 mL/min/100 g of bone). Osteocyte death occurs within 12–48 hours of ischemia. Over subsequent weeks to months, a reactive repair zone of granulation tissue and revascularization attempts forms at the necrotic margin; however, in most patients this reparative response is insufficient, and mechanical loading converts the weakened subchondral plate into a crescent-sign fracture visible on MRI, the gold-standard early diagnostic tool (sensitivity >95% for Stage I disease).
The contemporary standard of care is stage-dependent and multidisciplinary. ARCO Stages I and II are addressed with joint-preservation strategies including core decompression (with or without tantalum rod implantation, growth factors, or concentrated bone marrow aspirate containing mesenchymal stem cells), free vascularized fibular graft (FVFG), and bisphosphonate or lipid-lowering pharmacotherapy as adjuncts. ARCO Stages III and IV, characterized by subchondral collapse and joint-space narrowing, generally require total hip arthroplasty (THA) or total knee arthroplasty (TKA), now increasingly performed with robotic-arm assistance (e.g., Mako SmartRobotics™) for sub-millimeter implant positioning and optimized soft-tissue balancing, which is critical in younger, higher-demand AVN patients.
Candidates
• **Ideal candidates for joint-preservation (core decompression / FVFG / biologics):**
- ARCO / Ficat-Arlet Stage I or II AVN confirmed on MRI (T1-weighted low-signal crescent, T2 double-line sign)
- Necrotic lesion involving <30% of the femoral head (Kerboul combined necrotic angle <200°)
- Age <50 years, with high functional demand and significant remaining life expectancy
- Adequate bone stock confirmed on CT quantitative analysis
- Willingness to comply with protected weight-bearing for 6–12 weeks post-procedure
• **Ideal candidates for total joint arthroplasty (THA/TKA):**
- ARCO Stage III (crescent sign / subchondral collapse) or Stage IV (joint-space narrowing, secondary OA)
- Intractable hip or knee pain (VAS ≥7/10) unresponsive to conservative measures
- Harris Hip Score (HHS) <70 or WOMAC score indicating severe functional limitation
- Medically fit for general or regional anesthesia (ASA Class I–III)
• **Required pre-operative diagnostics:**
- MRI of affected joint with gadolinium contrast (gold standard; mandatory for staging)
- Weight-bearing plain radiographs (AP + lateral) for Ficat-Arlet staging
- CT scan for 3D necrotic volume calculation and subchondral integrity assessment
- Dual-energy X-ray absorptiometry (DEXA) for bone mineral density
- Full blood panel: CBC, ESR, CRP, coagulation profile (PT/INR, aPTT), fasting lipid panel, fasting glucose/HbA1c
- Thrombophilia screen (protein C, protein S, antiphospholipid antibodies, factor V Leiden) — especially relevant in idiopathic AVN
- Hemoglobin electrophoresis if sickle cell disease is suspected
- Echocardiogram (ECHO) and cardiology clearance for patients >60 years or with known cardiac history
- Chest X-ray and anesthetic pre-assessment
• **Relative and absolute contraindications:**
- Active systemic infection or bacteremia (absolute contraindication to elective arthroplasty)
- Uncontrolled coagulopathy or active anticoagulation that cannot be safely bridged
- Severe peripheral vascular disease compromising wound healing
- BMI >40 (relative contraindication; optimization advised prior to surgery)
- Uncontrolled diabetes mellitus (HbA1c >9%; optimization to <8% preferred pre-operatively)
- Active malignancy with bone metastases at the operative site
- Severe cardiopulmonary compromise precluding safe anesthesia (ASA Class IV–V)
Procedure
**1. Conservative & Pharmacological Management (Stage I, small lesions)** Protected weight-bearing (crutches / walker) for 6–12 weeks reduces mechanical stress on the necrotic segment. Bisphosphonates (alendronate 70 mg/week or zoledronic acid 5 mg IV annually) inhibit osteoclast-mediated subchondral resorption and have demonstrated slowed progression in randomized trials. Statins (atorvastatin, lovastatin) address the lipid-mediated dysregulation implicated in steroid-associated AVN. Vasodilators (iloprost, a prostacyclin analogue) administered intravenously over 5-day cycles have shown promise in European trials for reducing intraosseous pressure and pain. These measures are best considered adjuncts or short-term bridges, not definitive therapy.
**2. Core Decompression (Stage I–II)** The most widely performed joint-preservation procedure. Under fluoroscopic or CT guidance, one or more percutaneous 8–10 mm cannulated drill tracks are created from the lateral femoral cortex into the necrotic zone, reducing pathologically elevated intraosseous pressure (which can exceed 40 mmHg in AVN vs. normal 15–20 mmHg) and stimulating revascularization. Multiple small-diameter (3.5 mm) drilling (Phemister technique) minimizes cortical weakening. Augmentation strategies significantly improve outcomes: - **Tantalum Rod Implantation (Trabecular Metal™):** A highly porous (80% porosity) tantalum rod inserted into the decompression tract provides immediate structural support preventing subchondral collapse while osseointegration occurs. Particularly effective for Stage II lesions with intact articular surface. - **Concentrated Bone Marrow Aspirate (CBMA) / Mesenchymal Stem Cell (MSC) Augmentation:** Autologous MSCs harvested from the posterior iliac crest under centrifugation (Harvest SmartPrep™ or Magellan™ systems) and injected into the necrotic void provide osteogenic, angiogenic, and anti-apoptotic signaling, improving healing rates by 20–30% over core decompression alone in RCT data. - **Platelet-Rich Plasma (PRP):** Used adjunctively to deliver concentrated growth factors (PDGF, TGF-β1, VEGF) supporting neovascularization.
**3. Free Vascularized Fibular Graft (FVFG) — Stage II–III (pre-collapse or early collapse)** Considered the gold-standard joint-preservation procedure for younger patients (<45 years) with larger necrotic lesions (Kerboul angle 200–250°) or early collapse. A segment of fibula with its peroneal vascular pedicle is harvested and microsurgically anastomosed to the lateral femoral circumflex vessels within the hip. The graft simultaneously provides structural support and a living vascular conduit directly into the necrotic zone. Reported femoral head survival rates of 80–90% at 5 years in experienced centers. Technically demanding — requires a microvascular surgery team with a dedicated operating time of 4–6 hours.
**4. Non-Vascularized Bone Grafting with Trap-Door / Lightbulb Procedure** Indicates Stage II–IIIa disease. A cortical window is created in the femoral neck (trap-door technique), necrotic bone curetted, and the void filled with cancellous autograft ± synthetic bone substitutes (calcium phosphate, hydroxyapatite). Less technically demanding than FVFG but with lower long-term efficacy for large lesions.
**5. Total Hip Arthroplasty (THA) — Stage III–IV** The definitive intervention for advanced AVN with articular collapse. AVN patients undergoing THA are typically younger than primary OA patients, demanding implant systems with superior longevity: - **Bearing surfaces:** Ceramic-on-ceramic (CoC, e.g., Biolox Delta™) or ceramic-on-highly crosslinked polyethylene (CoXLPE) — preferred for reduced wear debris and osteolysis risk over a 20–30 year horizon. - **Fixation:** Cementless press-fit stems and cups with porous titanium / trabecular metal coating (e.g., Zimmer Biomet Taperloc, Smith+Nephew REDAPT) to achieve durable biologic fixation in younger bone. - **Robotic-Arm Assisted THA (Mako SmartRobotics™, ROSA Hip™):** Pre-operative CT-based 3D planning defines optimal cup abduction (38–42°) and anteversion (15–20°) angles and stem alignment. The robotic arm enforces a defined cutting boundary intraoperatively, reducing component malposition — the leading cause of dislocation and early revision — by up to 50% versus conventional THA. Particularly valuable in AVN patients who often have distorted proximal femoral anatomy from prior decompression procedures or disease progression.
**6. Total Knee Arthroplasty (TKA) — AVN of Femoral Condyle / Tibial Plateau (Stage III–IV)** For condylar AVN progressing to secondary OA. Robotic-assisted TKA (Mako, NAVIO™) ensures precise resection and balanced flexion-extension gaps, critical for long-term implant survival. Unicompartmental knee arthroplasty (UKA) is an option when AVN is isolated to a single compartment with an intact ligamentous envelope.
**7. Emerging & Investigational Therapies** - **Extra-corporeal Shock Wave Therapy (ESWT):** Non-invasive; stimulates angiogenesis and bone remodeling via mechanotransduction; evidence supports use as adjunct in Stage I–II. - **Hyperbaric Oxygen Therapy (HBOT):** Enhances oxygen delivery to ischemic tissue; used adjunctively in some centers, particularly for dysbaric AVN. - **Gene Therapy & Growth Factor Delivery (BMP-2, VEGF gene vectors):** Under active clinical trial investigation.
Cost of Avascular Necrosis Treatment: India vs. UAE
The cost of AVN treatment varies significantly based on the procedure type (core decompression versus robotic total hip/knee replacement), implant selection (standard vs. ceramic-on-ceramic or trabecular metal components), and the destination chosen. Both India and the UAE offer internationally accredited facilities with fellowship-trained orthopedic surgeons and access to the same generation of robotic systems and implant brands used in the United States and Europe — but at substantially lower cost. India typically offers savings of 50–70% versus comparable Western treatment, while the UAE provides a premium, luxury-medical experience at 30–50% below comparable US or UK pricing. The ranges below cover the full clinical spectrum from core decompression to complex robotic total hip replacement with premium implants.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $3,500 – $12,000 | ~48% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $8,000 – $22,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
**Phase 1: Pre-Arrival & Remote Consultation (2–4 weeks before travel)**
• Upload MRI, CT, X-rays, and blood reports to GAF Healthcare's secure patient portal for remote review by the treating orthopedic surgeon.
• Video teleconsultation with specialist: staging confirmed, surgical plan defined (joint-preservation vs. arthroplasty), implant selection discussed.
• GAF Healthcare coordinates e-Medical Visa application (India) or visa-on-arrival / UAE Golden Visa facilitation.
• Pre-operative optimization protocol issued: bisphosphonate/statin management, HbA1c control if diabetic, anticoagulation bridging plan.
• Attendant accommodation and airport transfer pre-booked.
**Phase 2: Arrival & Pre-Operative Assessment (Days 1–2)**
• Airport pickup by dedicated GAF Healthcare coordinator.
• Hospital admission: full pre-operative workup completed — MRI review, CT 3D planning for robotic surgery uploaded to Mako system, ECHO if indicated, anesthetic assessment, DVT risk stratification (Caprini score), cross-match and blood banking.
• Pre-operative physiotherapy assessment establishes baseline functional scores (Harris Hip Score / WOMAC / Oxford Score).
• Informed consent obtained with interpreter present if required.
• Nutritional optimization: high-protein supplementation and iron optimization initiated.
**Phase 3: Surgical Procedure (Day 3 or 4)**
• *For Core Decompression + CBMA:* 60–90 minutes under spinal or general anesthesia. Fluoroscopic guidance. Percutaneous — typically no skin incision >1 cm. Day surgery or 1-night stay. Weight-bearing with crutches commences same day.
• *For FVFG:* 4–6 hours under general anesthesia. Two surgical teams (hip and fibula harvest). 3–5 night ICU-adjacent monitoring for graft vascularity checks. Non-weight-bearing for 6 weeks.
• *For Robotic-Assisted THA/TKA:* 90–120 minutes. Anterior or posterolateral approach (hip); medial parapatellar approach (knee). Intraoperative robotic arm guidance. Regional (spinal + nerve block) anesthesia preferred to minimize opioid use and facilitate same-day mobilization protocol.
**Phase 4: Immediate Post-Operative Care (Days 1–5 post-surgery)**
• Multimodal analgesia protocol: celecoxib, acetaminophen, peripheral nerve block (adductor canal for TKA; fascia iliaca for THA) — opioid-sparing.
• For THA/TKA: Day 1 post-op: physical therapist-supervised standing and first steps with a walker. Day 2: stair training initiated. DVT prophylaxis: rivaroxaban 10 mg or enoxaparin as per weight, continued for 4–6 weeks.
• Wound monitoring for hematoma, infection, or neurovascular compromise.
• Drain removal Day 1–2. Suture/staple removal Day 10–14 (often managed at local clinic post-discharge).
**Phase 5: In-Country Rehabilitation (Weeks 1–6)**
• Outpatient physiotherapy: daily sessions at hospital-affiliated rehab center or GAF Healthcare's partnered facility.
- Week 1–2 (THA/TKA): gait training, hip precautions education, quadriceps/glute activation, ROM exercises.
- Week 3–4: progressive weight-bearing without walker (THA), cycling on stationary bike, pool hydrotherapy if available.
- Week 5–6: functional mobility assessment; stair climbing independence; VAS pain target <3/10; ROM: hip flexion >90° (THA), knee flexion >110° (TKA).
• *For core decompression patients:* Week 1–2 crutch-assisted weight-bearing; return to desk work possible from Week 2. Physiotherapy is less intensive but compliance with protected weight-bearing is critical.
**Phase 6: Fit-to-Fly Assessment & Discharge Planning**
• Surgeon conducts formal fit-to-fly clinical review.
- Core Decompression: typically fit to fly at 3–4 weeks post-procedure; compression stockings and in-flight ambulation protocol issued.
- FVFG: 6 weeks minimum (graft vascularity must be confirmed via Doppler ultrasound).
- THA/TKA: 6–8 weeks post-op; mandatory DVT screen (lower-limb duplex ultrasound) within 48 hours of planned flight; aisle seating and compression stockings mandated; extended-duration DVT prophylaxis prescription provided.
• Discharge pack includes: full operative report, implant sticker/card (airport security), post-operative medication list, physiotherapy continuation plan, 6-week and 3-month follow-up protocols (remote teleconsultation with GAF Healthcare).
**Phase 7: Long-Term Follow-Up (Months 1–24)**
• Remote teleconsultation at 6 weeks, 3 months, 6 months, and 12 months post-procedure.
• X-ray / MRI imaging performed at patient's local facility; images shared via GAF portal for remote review.
• Target milestones: return to sedentary work (4–6 weeks); light walking without aid (8–10 weeks); return to low-impact sport — swimming, cycling (3–6 months); return to high-impact activity only with surgeon approval (>12 months for arthroplasty).
Risks & Considerations
AVN treatment carries a spectrum of procedure-specific risks that every patient should understand before travel. For core decompression, the principal risks include femoral neck stress fracture (1–3%, mitigated by using multiple small-diameter drills rather than a single large tract), failure to halt disease progression requiring conversion to arthroplasty (15–40% at 5 years depending on stage and lesion size), and minor wound infection at the portal site. Free vascularized fibular grafting carries additional risks inherent to microsurgery: vascular anastomosis thrombosis causing graft failure (5–10% in experienced hands), donor-site morbidity including ankle instability or transient common peroneal nerve palsy (toe drop, usually resolving within 3–6 months), and prolonged non-weight-bearing imposing significant lifestyle disruption. Robotic-assisted total hip and knee arthroplasty carries the well-characterized risks of major joint replacement: periprosthetic joint infection (0.5–1.5%), deep vein thrombosis and pulmonary embolism (DVT rate 1–3% with pharmacoprophylaxis), periprosthetic fracture (<1%), leg length discrepancy (reduced but not eliminated by robotic guidance), dislocation (0.5–1.5% with anterior approach and robotic cup positioning), and neurovascular injury (<0.5%). Because AVN patients are often younger and may have underlying risk factors (corticosteroid use, coagulopathy, sickle cell disease), a thorough medical optimization protocol — including thrombophilia management and bone quality assessment — is conducted by GAF Healthcare's coordinating physicians prior to surgical clearance. Implant longevity is a legitimate long-term concern in young AVN patients; the risk of revision THA at 15–20 years is estimated at 8–15%, which is why ceramic bearing surfaces and high-offset, cementless implant systems are preferentially selected. All risks and their mitigation strategies are discussed in detail during the GAF Healthcare pre-operative teleconsultation.
Top Hospitals for Avascular Necrosis Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Manipal Hospitals
Bengaluru, India
Manipal Hospitals Dwarka
New Delhi, India
Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE
Kings College Hospital Dubai
Dubai, UAE
Top Doctors for Avascular Necrosis Treatment
Internationally trained specialists in Orthopedics. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. H. Vinay Kumar
MBBS, MS, Fellowship in Arthroscopy & Sports Medicine, Fellowship in Joint Replacement
Orthopedic Surgeon
Yashoda Hospitals, Secunderabad, Hyderabad, India
10+ Yearsof experience
Dr. H. Vinay Kumar is a Senior Consultant Orthopedic Surgeon at Yashoda Hospitals in Secunderabad, Hyderabad, with over 10 years of clinical experience in advanced joint surgery and arthroscopy. He holds an MS in Orthopedics from SCB Government Medical College, Cuttack, and has completed specialized fellowships in Arthroscopy & Sports Medicine (Ahmedabad) and Joint Replacement (Hyderabad), positioning him at the forefront of minimally invasive orthopedic… Read more
Dr. Hemant Sharma
MBBS, DNB (Orthopaedics), MRCS (England), FRCS (England)
Orthopedic Surgeon
Marengo Asia Hospitals, Gurugram, India
28+ Yearsof experience
Dr. Hemant Sharma is Chairman of Orthopaedics & Joint Replacement and Spine Surgery at Marengo Asia Hospitals in Gurugram, bringing over 28 years of clinical expertise to orthopedic surgery. A Fellow of the Royal College of Surgeons of England and holder of a postgraduate DNB in Orthopaedics, Dr. Sharma trained extensively in both India and England, spending 11 years in each country to refine his surgical craft. His academic foundation began with an MBBS… Read more
Dr. Jitendra Kataria
MBBS, D Ortho, DNB Ortho, Fellowship in Arthroplasty, Diploma in Medico-Legal Systems
Orthopedic Surgeon
Gleneagles Global Hospitals, Mumbai, India
10+ Yearsof experience
Dr. Jitendra Kataria is a Consultant Orthopedic Surgeon at Gleneagles Global Hospitals in Mumbai with over 10 years of dedicated clinical experience. He holds a comprehensive postgraduate pedigree, including a DNB in Orthopaedics from P. D. Hinduja Hospital and a specialized Fellowship in Arthroplasty. His advanced training equips him with technical proficiency across the full spectrum of orthopedic care. Dr. Kataria's clinical expertise spans complex… Read more
Dr. Karthik Gajapathy
MBBS, DNB (Ortho)
Orthopedic Surgeon
Gleneagles Hospitals, Bengaluru, India
25+ Yearsof experience
Dr. Karthik Gajapathy is a Senior Consultant in Orthopedic Surgery with over 25 years of dedicated clinical practice in Bengaluru, India. Holding qualifications in MBBS and DNB (Orthopedics), he has established himself as a compassionate and highly skilled practitioner in joint replacement and orthopedic trauma care. His extensive experience spans the full spectrum of orthopedic conditions, from degenerative joint disease to complex fracture management.… Read more
Dr. M N Sehar
MBBS, MS, Dip.Orth, FRCS, FRCS Orth (UK)
Orthopedic Surgeon
Indraprastha Apollo Hospital, New Delhi, India
30+ Yearsof experience
Dr. M N Sehar is a Senior Consultant in Orthopedic Surgery at Indraprastha Apollo Hospital in New Delhi, bringing over 30 years of dedicated experience in musculoskeletal care. He holds prestigious qualifications including MBBS, MS, Dip.Orth, FRCS, and FRCS Orth (UK) from the Royal College of Surgeons—reflecting his rigorous training across India and the United Kingdom. His clinical focus spans advanced joint replacement surgery, arthroscopic techniques,… Read more
Patient Success Story
Frequently Asked Questions — Avascular Necrosis Treatment
The cost of AVN treatment depends on the stage of disease and the surgical procedure required. In India, joint-preservation procedures such as core decompression with stem cell augmentation or tantalum rod implantation typically cost USD 3,500–6,000, while advanced procedures such as robotic-assisted total hip arthroplasty (THA) with ceramic-on-ceramic bearings range from USD 7,000–12,000 — inclusive of surgeon fees, anesthesia, hospital stay, implants, and standard post-operative medications at NABH/JCI-accredited centers. In the UAE (Dubai / Abu Dhabi), the equivalent core decompression procedures cost approximately USD 8,000–12,000, and robotic THA with premium implants ranges from USD 15,000–22,000 at JCI/DHA-licensed hospitals. India is generally 50–70% more affordable than the UAE for equivalent clinical quality, making it the preferred choice for patients prioritizing cost. The UAE offers the advantage of proximity for Middle Eastern and European patients, luxury infrastructure, Arabic-language care teams, and seamless international health insurance processing. GAF Healthcare provides transparent, itemized cost estimates for each patient's specific treatment plan at no charge during the initial consultation.
The minimum in-country stay before you are cleared to fly home depends on the specific procedure performed. For core decompression (with or without stem cell augmentation or tantalum rod), patients are typically assessed as fit to fly within 3–4 weeks, provided wound healing is complete, pain is controlled, and crutch-assisted ambulation is established. For free vascularized fibular grafting (FVFG), a minimum of 6 weeks is required to confirm vascular anastomosis patency via Doppler ultrasound and to ensure the graft is not at risk during the physiological stress of a long-haul flight. For robotic-assisted total hip arthroplasty (THA) or total knee arthroplasty (TKA), the internationally recommended minimum is 6–8 weeks post-surgery. Before any international flight is authorized, your GAF Healthcare orthopedic team performs a formal fit-to-fly assessment that includes a lower-limb deep vein thrombosis (DVT) screen by duplex ultrasound, gait evaluation, and wound inspection. All patients flying post-arthroplasty receive a DVT prophylaxis plan (extended rivaroxaban or enoxaparin), compression stockings, aisle seating advice, and an in-flight mobilization protocol to minimize thromboembolic risk during transit.
Success rates for AVN treatment are highly stage-dependent and vary by procedure. For joint-preservation interventions in early-stage AVN (ARCO Stage I–II with intact articular surface and Kerboul combined necrotic angle <200°), core decompression with mesenchymal stem cell augmentation achieves femoral head survival — defined as avoidance of arthroplasty — in approximately 70–85% of patients at 5 years. Free vascularized fibular grafting (FVFG) in experienced microsurgical centers achieves femoral head survival of 80–90% at 5 years for carefully selected Stage II–IIIa cases, making it the most effective joint-preservation option for larger lesions. For advanced-stage AVN (ARCO Stage III–IV) requiring total hip arthroplasty, robotic-assisted THA with contemporary cementless, ceramic-bearing implants demonstrates prosthetic survivorship exceeding 95% at 10 years and approximately 85–90% at 20 years in registry data — outcomes that are particularly important given the younger age profile of most AVN patients. The key determinant of success is early diagnosis: patients presenting at Stage I or II have dramatically better outcomes from joint-preserving surgery than those who present with established subchondral collapse. GAF Healthcare's pre-travel remote consultation is designed specifically to ensure each patient is stratified correctly and matched to the procedure most likely to achieve the best long-term result for their individual disease characteristics.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end non-medical support designed specifically for international orthopedic patients traveling to India or the UAE.
**India (New Delhi, Mumbai, Chennai, Bengaluru, Hyderabad):**
• e-Medical Visa (e-MV) application assistance: GAF Healthcare's visa support team prepares and submits the complete e-MV application package (letter from Indian hospital, medical records summary, visa photographs) through the official Indian government portal. e-Medical Visas are typically approved within 3–5 business days and allow a stay of up to 60 days with two extensions, fully covering AVN treatment and in-country rehabilitation. Two attendant e-Medical Visas (e-MV companion category) are processed simultaneously.
• Partner hospitals hold NABH accreditation (National Accreditation Board for Hospitals) and JCI (Joint Commission International) accreditation, ensuring internationally benchmarked clinical standards.
• Airport-to-hospital transfer in an accessible, air-conditioned medical-grade vehicle with a wheelchair ramp if required.
• Dedicated multilingual patient coordinator (languages available: English, Arabic, Russian, French, Swahili, Bangla, Pashto) assigned for the entire duration of stay.
• Attendant accommodation: serviced apartments adjacent to the hospital (typically USD 40–80/night) or hospital guest house pre-booked by GAF Healthcare.
• SIM card with data plan provided on arrival for uninterrupted communication.
• Pharmacy coordination: post-operative medications, DVT prophylaxis injections, and assistive devices (crutches, walker, compression stockings) procured and delivered to the patient's room.
**UAE (Dubai, Abu Dhabi, Sharjah):**
• Visa facilitation: citizens of 170+ countries receive UAE visa-on-arrival (14–30 days, extendable) or UAE Electronic Travel Authorization (ETA). GAF Healthcare issues a hospital appointment letter for visa extension requests where required. GCC residents and most Western nationals require no pre-arrangement.
• Partner hospitals carry JCI accreditation and DHA (Dubai Health Authority) or DOH (Abu Dhabi Department of Health) licensing, the UAE's dual-tier quality benchmarking system.
• Dedicated luxury medical concierge service: private airport transfers (SUV or accessible van), hotel bookings adjacent to hospital (3–5 star, with room-service access for post-operative dietary needs), and in-room physiotherapy coordination.
• Multilingual coordinator (Arabic, English, Russian, Hindi, Urdu, French available).
• Health insurance billing support: GAF Healthcare's team assists in pre-authorization with international health insurers where AVN treatment is a covered indication.
• Telemedicine follow-up appointments with the treating UAE surgeon arranged at 6 weeks, 3 months, and 6 months post-discharge, accessible from the patient's home country via encrypted video platform.